The move is almost certainly the final nail in the coffin of the embattled company known for its mail-order DNA testing kit. Since going public through a merger with a special purpose acquisition company (SPAC) in 2021, 23andMe has never turned a profit. Its IPO day price was $10; so far, it has yet to […]